{"id":7776,"date":"2021-02-01T22:49:13","date_gmt":"2021-02-01T11:49:13","guid":{"rendered":"https:\/\/mvec.mcri.edu.au\/?p=7776"},"modified":"2021-02-01T22:49:13","modified_gmt":"2021-02-01T11:49:13","slug":"novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial","status":"publish","type":"post","link":"https:\/\/mvec.mcri.edu.au\/vi\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/","title":{"rendered":"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial"},"content":{"rendered":"<p>Novavax have released interim results for both its UK phase III clinical trial as well as for the phase 2b studies being conducted in South Africa.<\/p>\n<p>The UK phase III clinical trial involves more than 15,000 participants aged 18-84 years. During a period of high transmission with the UK variant of SARS-CoV-2, the preliminary results show an efficacy rate of 89.3%. After review of the vaccine safety database it has also been reported that any adverse events were balanced between both the vaccine and the placebo groups and any serious or severe side effects occurred at low levels.<\/p>\n<p>In the South African phase 2b clinical trial, an efficacy rate of 60% was seen in the HIV-negative cohort, with an overall 49.4% efficacy rate seen across the total 4,400 trial participants (both HIV-negative and HIV positive individuals). During the time of the trial, the South African variant of SARS-CoV-2 was widely circulating.<\/p>\n<p>The Novavax <a href=\"https:\/\/mvec.mcri.edu.au\/references\/novavax-covid-19-vaccine\/\">COVID-19 vaccine candidate<\/a>\u00a0is a protein-based vaccine utilising a nanoparticle technology\u00a0<a href=\"https:\/\/mvec.mcri.edu.au\/references\/covid-19-vaccine-platforms\/\">platform<\/a>.<\/p>\n<p>To read the full press release follow the link below:<\/p>\n<p><a href=\"https:\/\/www.novavax.com\/covid-19-coronavirus-vaccine-candidate-updates\" target=\"_blank\" rel=\"noopener\">Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial<\/a><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Novavax have released interim results for both its UK phase III clinical trial as well as for the phase 2b<\/p>","protected":false},"author":375,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_lmt_disableupdate":"","_lmt_disable":"","footnotes":"","_wp_rev_ctl_limit":""},"categories":[87,8,10],"tags":[],"class_list":["post-7776","post","type-post","status-publish","format-standard","hentry","category-news","category-covid-19","category-external"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial - The Melbourne Vaccine Education Centre (MVEC)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mvec.mcri.edu.au\/vi\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/\" \/>\n<meta property=\"og:locale\" content=\"vi_VN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial - The Melbourne Vaccine Education Centre (MVEC)\" \/>\n<meta property=\"og:description\" content=\"Novavax have released interim results for both its UK phase III clinical trial as well as for the phase 2b\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mvec.mcri.edu.au\/vi\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"The Melbourne Vaccine Education Centre (MVEC)\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-01T11:49:13+00:00\" \/>\n<meta name=\"author\" content=\"Rachael McGuire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u0110\u01b0\u1ee3c vi\u1ebft b\u1edfi\" \/>\n\t<meta name=\"twitter:data1\" content=\"Rachael McGuire\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u01af\u1edbc t\u00ednh th\u1eddi gian \u0111\u1ecdc\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 ph\u00fat\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\\\/\"},\"author\":{\"name\":\"Rachael McGuire\",\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/#\\\/schema\\\/person\\\/571925ba39f95adf6ba3463422a752d7\"},\"headline\":\"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial\",\"datePublished\":\"2021-02-01T11:49:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\\\/\"},\"wordCount\":189,\"commentCount\":0,\"articleSection\":[\"Show all\",\"COVID-19\",\"External News\"],\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/mvec.mcri.edu.au\\\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\\\/\",\"url\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\\\/\",\"name\":\"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial - The Melbourne Vaccine Education Centre (MVEC)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/#website\"},\"datePublished\":\"2021-02-01T11:49:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/#\\\/schema\\\/person\\\/571925ba39f95adf6ba3463422a752d7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\\\/#breadcrumb\"},\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mvec.mcri.edu.au\\\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/#website\",\"url\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/\",\"name\":\"The Melbourne Vaccine Education Centre (MVEC)\",\"description\":\"Find all your vaccine related infos here.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vi\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/#\\\/schema\\\/person\\\/571925ba39f95adf6ba3463422a752d7\",\"name\":\"Rachael McGuire\",\"url\":\"https:\\\/\\\/mvec.mcri.edu.au\\\/vi\\\/author\\\/rachael-mcguire\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial - The Melbourne Vaccine Education Centre (MVEC)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mvec.mcri.edu.au\/vi\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/","og_locale":"vi_VN","og_type":"article","og_title":"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial - The Melbourne Vaccine Education Centre (MVEC)","og_description":"Novavax have released interim results for both its UK phase III clinical trial as well as for the phase 2b","og_url":"https:\/\/mvec.mcri.edu.au\/vi\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/","og_site_name":"The Melbourne Vaccine Education Centre (MVEC)","article_published_time":"2021-02-01T11:49:13+00:00","author":"Rachael McGuire","twitter_card":"summary_large_image","twitter_misc":{"\u0110\u01b0\u1ee3c vi\u1ebft b\u1edfi":"Rachael McGuire","\u01af\u1edbc t\u00ednh th\u1eddi gian \u0111\u1ecdc":"1 ph\u00fat"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mvec.mcri.edu.au\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/#article","isPartOf":{"@id":"https:\/\/mvec.mcri.edu.au\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/"},"author":{"name":"Rachael McGuire","@id":"https:\/\/mvec.mcri.edu.au\/#\/schema\/person\/571925ba39f95adf6ba3463422a752d7"},"headline":"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial","datePublished":"2021-02-01T11:49:13+00:00","mainEntityOfPage":{"@id":"https:\/\/mvec.mcri.edu.au\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/"},"wordCount":189,"commentCount":0,"articleSection":["Show all","COVID-19","External News"],"inLanguage":"vi","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/mvec.mcri.edu.au\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/mvec.mcri.edu.au\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/","url":"https:\/\/mvec.mcri.edu.au\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/","name":"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial - The Melbourne Vaccine Education Centre (MVEC)","isPartOf":{"@id":"https:\/\/mvec.mcri.edu.au\/#website"},"datePublished":"2021-02-01T11:49:13+00:00","author":{"@id":"https:\/\/mvec.mcri.edu.au\/#\/schema\/person\/571925ba39f95adf6ba3463422a752d7"},"breadcrumb":{"@id":"https:\/\/mvec.mcri.edu.au\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/#breadcrumb"},"inLanguage":"vi","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mvec.mcri.edu.au\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mvec.mcri.edu.au\/novavax-covid-19-vaccine-demonstrates-89-3-efficacy-in-uk-phase-3-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mvec.mcri.edu.au\/"},{"@type":"ListItem","position":2,"name":"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial"}]},{"@type":"WebSite","@id":"https:\/\/mvec.mcri.edu.au\/#website","url":"https:\/\/mvec.mcri.edu.au\/","name":"Trung t\u00e2m gi\u00e1o d\u1ee5c v\u1eafc xin Melbourne (MVEC)","description":"T\u00ecm t\u1ea5t c\u1ea3 c\u00e1c th\u00f4ng tin li\u00ean quan \u0111\u1ebfn v\u1eafc-xin c\u1ee7a b\u1ea1n \u1edf \u0111\u00e2y.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mvec.mcri.edu.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vi"},{"@type":"Person","@id":"https:\/\/mvec.mcri.edu.au\/#\/schema\/person\/571925ba39f95adf6ba3463422a752d7","name":"Rachel McGuire","url":"https:\/\/mvec.mcri.edu.au\/vi\/author\/rachael-mcguire\/"}]}},"modified_by":"Rachael McGuire","_links":{"self":[{"href":"https:\/\/mvec.mcri.edu.au\/vi\/wp-json\/wp\/v2\/posts\/7776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mvec.mcri.edu.au\/vi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mvec.mcri.edu.au\/vi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mvec.mcri.edu.au\/vi\/wp-json\/wp\/v2\/users\/375"}],"replies":[{"embeddable":true,"href":"https:\/\/mvec.mcri.edu.au\/vi\/wp-json\/wp\/v2\/comments?post=7776"}],"version-history":[{"count":0,"href":"https:\/\/mvec.mcri.edu.au\/vi\/wp-json\/wp\/v2\/posts\/7776\/revisions"}],"wp:attachment":[{"href":"https:\/\/mvec.mcri.edu.au\/vi\/wp-json\/wp\/v2\/media?parent=7776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mvec.mcri.edu.au\/vi\/wp-json\/wp\/v2\/categories?post=7776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mvec.mcri.edu.au\/vi\/wp-json\/wp\/v2\/tags?post=7776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}